비타민 D 독성 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 환자층별, 용도별, 지역별, 부문별 예측(2026-2033년)

Vitamin D Toxicity Market Summary

The global vitamin D toxicity market size was estimated at USD 170.58 million in 2025 and is expected to reach by USD 461.83 million by 2033, growing at a CAGR of 13.31% from 2026 to 2033. The increasing use of high-dose vitamin D supplements, rising awareness of vitamin D deficiency, and the growing adoption of preventive health practices drive the market growth.

Excessive intake of vitamin D can lead to hypercalcemia, which may result in symptoms such as nausea, renal dysfunction, bone pain, and cardiovascular complications. As supplement consumption and therapeutic dosing continue to increase, the need for routine laboratory monitoring has become more critical to detect elevated vitamin D levels early and prevent associated metabolic and systemic complications.

The growth of the vitamin D toxicity diagnostics market is driven by the increasing consumption of high-dose vitamin D supplements and fortified nutritional products worldwide. Rising awareness of vitamin D deficiency, combined with preventive health trends, has led to widespread supplementation, often without medical supervision. Excessive intake can lead to hypervitaminosis D and hypercalcemia, thereby increasing the need for routine diagnostic monitoring. According to the National Institutes of Health, prolonged intake above recommended upper limits may cause adverse health effects, underscoring the importance of laboratory testing to monitor vitamin D levels and prevent toxicity-related complications.

The expanding adoption of preventive healthcare and routine wellness screening is further supporting market growth. Vitamin D testing is increasingly incorporated into annual health checkups, metabolic panels, and preventive screening programs, particularly in regions with high deficiency prevalence. Large diagnostic service providers have expanded wellness testing portfolios that include vitamin D screening as part of comprehensive health assessments, reflecting a shift toward proactive health management. This growing emphasis on early detection and preventive care is increasing testing volumes and supporting demand for toxicity monitoring.

Technological advancements in automated immunoassay analyzers and laboratory platforms are improving the accuracy, efficiency, and scalability of vitamin D testing. High-throughput systems enable precise measurement of serum 25-hydroxyvitamin D concentrations, which is essential for identifying toxic levels and guiding clinical intervention. For instance, Abbott developed automated vitamin D assays for its ARCHITECT and Alinity platforms to support high-volume clinical testing and improved laboratory workflow efficiency. These innovations are enhancing diagnostic reliability and enabling healthcare providers to monitor patients more effectively.

The increasing prevalence of osteoporosis, chronic kidney disease, and metabolic disorders is elevating the clinical importance of vitamin D monitoring. Patients receiving long-term supplementation or therapeutic high-dose vitamin D therapy require periodic testing to avoid complications such as hypercalcemia, nephrocalcinosis, and renal dysfunction. Aging populations and a growing focus on bone health management are further expanding the patient base requiring monitoring. Clinical laboratories are increasingly utilizing advanced immunoassay and mass spectrometry methods to support endocrine and metabolic testing, strengthening the role of vitamin D diagnostics in chronic disease management.

Despite growing demand, the industry's expansion into vitamin D toxicity may be constrained by variability in testing standards, limited awareness of vitamin D toxicity risks, and cost considerations associated with routine monitoring. Differences in assay methodologies and reference ranges across laboratories can complicate the interpretation of results and clinical decision-making. In many regions, vitamin D testing is primarily performed to detect deficiency rather than toxicity, which may limit awareness of the risks of hypervitaminosis among both patients and healthcare providers. In addition, preventive testing may not be fully reimbursed in certain healthcare systems, restricting adoption in price-sensitive markets and slowing the uptake of routine toxicity monitoring.

Global Vitamin D Toxicity Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the vitamin D toxicity market report based on test type, patient group, end use, and region:

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Serum 25-hydroxyvitamin D [25(OH)D] Testing
• Serum Calcium Testing
• Serum Phosphate Testing
• Parathyroid Hormone (PTH) Testing
• Renal Function and Electrolyte Panels
• Patient Group Outlook (Revenue, USD Million, 2021 - 2033)
• Pediatric Population
• Adult Population
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Laboratories
• Independent Diagnostic Laboratories
• Specialty and Endocrinology Clinics
• Reference Laboratories
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
  • Denmark
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Type
  • 1.2.2. Patient Group
  • 1.2.3. End Use
  • 1.2.4. Regional Scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Vitamin D Toxicity Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising global consumption of vitamin D supplements
    • 3.2.1.2. Growth in preventive health screening and wellness testing
    • 3.2.1.3. Increasing physician awareness of hypercalcemia and metabolic complications
    • 3.2.1.4. Expansion of diagnostic laboratory networks and access
    • 3.2.1.5. Aging population and bone health management
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Low incidence and underdiagnosis of vitamin D toxicity
    • 3.2.2.2. Clinical guidelines discouraging unnecessary vitamin D testing
• 3.3. Vitamin D Toxicity Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Vitamin D Toxicity Market: Test Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Vitamin D Toxicity Market: Test Type Movement Analysis
• 4.3. Vitamin D Toxicity Market by Test Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Serum 25-hydroxyvitamin D [25(OH)D] Testing
  • 4.5.1. Serum 25-hydroxyvitamin D [25(OH)D] Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Serum Calcium Testing
  • 4.6.1. Serum Calcium Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Serum Phosphate Testing
  • 4.7.1. Serum Phosphate Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Parathyroid Hormone (PTH) Testing
  • 4.8.1. Parathyroid Hormone (PTH) Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Renal Function and Electrolyte Panels
  • 4.9.1. Renal Function and Electrolyte Panels Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Vitamin D Toxicity Market: Patient Group Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Vitamin D Toxicity Market: Patient Group Movement Analysis
• 5.3. Vitamin D Toxicity Market by Patient Group Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Pediatric Population
  • 5.5.1. Pediatric Population Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Adult Population
  • 5.6.1. Adult Population Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Vitamin D Toxicity Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Vitamin D Toxicity Market: End Use Movement Analysis
• 6.3. Vitamin D Toxicity Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Hospital Laboratories
  • 6.5.1. Hospital Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Independent Diagnostic Laboratories
  • 6.6.1. Independent Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Specialty and Endocrinology Clinics
  • 6.7.1. Specialty and Endocrinology Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Reference Laboratories
  • 6.8.1. Reference Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Vitamin D Toxicity Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.9. Rest of Europe
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework/ reimbursement structure
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Rest of Europe market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Rest of Asia Pacific
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Rest of Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Rest of Latin America
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. Rest of MEA
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Rest of MEA market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Recent Developments & Impact Analysis by Key Market Participants
• 8.3. Company Market Share Analysis, 2025
• 8.4. Key Company Profiles
  • 8.4.1. F. Hoffmann-La Roche Ltd (Roche Diagnostics)
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Abbott
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Siemens Healthineers AG
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Beckman Coulter, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Thermo Fisher Scientific, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. DiaSorin S.p.A.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. bioMerieux
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. QuidelOrtho Corporation
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Randox Laboratories Ltd.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Sysmex Corporation
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. Agilent Technologies, Inc.
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives